1. Home
  2. ORKA vs THW Comparison

ORKA vs THW Comparison

Compare ORKA & THW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ORKA
  • THW
  • Stock Information
  • Founded
  • ORKA 2004
  • THW 2015
  • Country
  • ORKA United States
  • THW United States
  • Employees
  • ORKA N/A
  • THW N/A
  • Industry
  • ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • THW Finance Companies
  • Sector
  • ORKA Health Care
  • THW Finance
  • Exchange
  • ORKA Nasdaq
  • THW Nasdaq
  • Market Cap
  • ORKA 354.2M
  • THW 391.1M
  • IPO Year
  • ORKA N/A
  • THW N/A
  • Fundamental
  • Price
  • ORKA $14.21
  • THW $10.37
  • Analyst Decision
  • ORKA Strong Buy
  • THW
  • Analyst Count
  • ORKA 8
  • THW 0
  • Target Price
  • ORKA $39.71
  • THW N/A
  • AVG Volume (30 Days)
  • ORKA 360.1K
  • THW 149.9K
  • Earning Date
  • ORKA 08-15-2025
  • THW 01-01-0001
  • Dividend Yield
  • ORKA N/A
  • THW 10.76%
  • EPS Growth
  • ORKA N/A
  • THW N/A
  • EPS
  • ORKA N/A
  • THW N/A
  • Revenue
  • ORKA N/A
  • THW N/A
  • Revenue This Year
  • ORKA N/A
  • THW N/A
  • Revenue Next Year
  • ORKA N/A
  • THW N/A
  • P/E Ratio
  • ORKA N/A
  • THW N/A
  • Revenue Growth
  • ORKA N/A
  • THW N/A
  • 52 Week Low
  • ORKA $5.49
  • THW $9.76
  • 52 Week High
  • ORKA $52.32
  • THW $14.89
  • Technical
  • Relative Strength Index (RSI)
  • ORKA N/A
  • THW 49.98
  • Support Level
  • ORKA N/A
  • THW $10.29
  • Resistance Level
  • ORKA N/A
  • THW $10.44
  • Average True Range (ATR)
  • ORKA 0.00
  • THW 0.13
  • MACD
  • ORKA 0.00
  • THW 0.01
  • Stochastic Oscillator
  • ORKA 0.00
  • THW 76.54

About ORKA Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

About THW abrdn World Healthcare Fund Shares of Beneficial Interest

Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies engaged in the healthcare industry. The company's investment portfolio comprises investments in different sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other areas. It also male into REIT Real Estate.

Share on Social Networks: